Among these inhibitors, the TLR4 inhibitor TAK—242 exhibits promise in the treatment of inflammatory diseases, including sepsis and acute lung injury, by obstructing the LPS—or HMGB1—mediated signaling pathways. This evidence concerns the gene HMGB1 and Sepsis.